Background. Duplex ultrasonography (DUS) can be used for treatment planning for lower extremity peripheral arterial disease (PAD), but has not replaced contrast-enhanced imaging such as computed tomography angiography (CTA). We assessed DUS-based treatment planning for consistency, confidence, and the value of additional CTA among multinational surgeons. Methods. Data from 12 patients with PAD were reviewed by 2 American vascular surgeons individually and 1 Dutch vascular department by consensus. Reviewers selected treatment based on DUS first and based on added CTA second. Agreement and consistency of treatment plans was assessed using kappa statistics (k). Imaging quality and therapeutic confidence were scored (1-5) and assessed with t-tests. Results. Of the 36 treatment plans formulated, additional CTA confirmed 27 (75%), changed 6 (17%), and supplemented 3 (8%) plans. The approach never changed when open revascularization was selected based on DUS (14 plans; 39%). Agreement between DUS-and CTA-based treatment planning was substantial, with a mean kappa (mk) of 0.68, but agreement between reviewers was fair (mk DUS, 0.24; mk CTA, 0.23). CTA received greater average scores than DUS for quality (4.36 vs 3.29; P < .0001) and confidence (4.36 vs 3.26; P < .0001). Reviewers often expressed the need for additional imaging after DUS (mean, 63%). Conclusion. PAD treatment planning based on CTA was mostly consistent with DUS-based treatment plans, although CTA was still felt to be needed to increase confidence. This observation suggests that to promote greater use of less invasive DUS imaging, not only improvement of DUS quality but also improvement of clinician confidence is required. (Surgery 2014;156:492-502.) 
DUS is the least expensive, and the only modality that does not require contrast or radiation exposure, as do angiography, CTA, and magnetic resonance angiography. When DUS was introduced in the 1980s, studies demonstrated that agreement between DUS and angiography was just as good as agreement between 2 clinicians who read the same angiograms both for detecting lesions and planning treatment. [6] [7] [8] In subsequent years, more studies demonstrated that DUS can be a safe alternative to angiography. [9] [10] [11] [12] [13] More recent publications advocate for an imaging work up with DUS only for PAD patients, because DUS has been shown to be a reliable tool for treatment planning. 3, 4, 14, 15 Nonetheless, the use of DUS is low in the United States, 16 and routine use of DUS as the sole imaging modality before intervention has, with the exception of some centers, 3, 15 not been accepted widely.
One of the barriers to greater adoption of DUS that has been described is the lack of confidence that clinicians seem to have in DUS, which further results in frequent orders for additional imaging. 17 Several factors contribute to this lack of confidence, including the operator dependency and manner of presentation of DUS results. Although for the assessment of hemodynamic impact of arterial lesions, 18, 19 DUS is less subjective than still images, DUS is dependent on the technician for interpretation and documentation of the examination. In addition, DUS results are presented in a written report, sometimes accompanied by color Doppler images; clinicians, however, are more familiar with images that more closely resemble a ''road map'' of the arterial vasculature, as provided by CTA or angiography. 1, 17, 20 To counter this problem, vascular diagnostic laboratories include a graphic presentation of the DUS findings in a map of the arterial system, often referred to as arterial mapping. 13 Based on clinical experience, we hypothesized that, not infrequently, additional imaging is ordered for the benefit of the treatment planning and therapeutic confidence of the clinicians. The purpose of this pilot study was to assess treatment planning based on DUS and based on additional imaging with CTA for consistency and confidence. We expected that both imaging modalities would be affected similarly by interobserver variability in treatment planning and that added CTA imaging would increase clinician confidence rather than affect the actual PAD treatment plan.
METHODS
Study cohort. The study protocol was approved by the Medical Ethics Committee of the Dutch and American hospitals. This study cohort consisted of 12 patients with claudication or critical limb ischemia who were presented consecutively at a weekly meeting of vascular surgeons and interventional radiologists at a tertiary teaching hospital in The Netherlands. These patients had undergone a routine work up for PAD at their center that included both DUS and CTA imaging. Patients with acute ischemia and acute limb threat were excluded. Those who were unable to undergo DUS or CTA imaging (eg, owing to extensive wounds or contrast allergy) or who did not receive both imaging modalities within a 1-month period of time were also excluded.
Dutch clinicians. After the clinical presentation of each case at the meeting, clinicians first formulated a treatment plan based on the findings of the DUS examination presented in a written report and arterial map. Subsequently, CTA imaging was added, and the clinicians decided on a treatment plan based on this CTA. The confidence in both treatment plans was scored on a numerical scale of 1 to 5, with 1 being least confident and 5 being most confident. The same scoring scale was used to score the imaging modalities for imaging quality. All decisions were made by consensus of the clinicians at the meeting, including faculty and senior residents of vascular surgery and interventional radiology.
American clinicians. The same patient data (anonymized and translated into English) were presented to 2 vascular surgeons at a tertiary teaching hospital in the United States with an average experience of >10 years in practice. A third U.S. vascular surgeon was excluded at an early stage, because we felt that our study protocol was not being met. This reviewer showed a disproportionally high level of discomfort with DUSbased treatment selection, which resulted in the selection of a conservative approach for nearly all DUS-based treatment plans. Furthermore, this reviewer commented that the selected conservative approach represented actually the wish to not make a decision at all and to proceed to conventional angiography instead, which we deemed not to be representative of the clinical decision-making process that we set out to assess in our study. Neither DUS nor CTA were standard work up for PAD because angiography was the routinely used imaging modality for these patients at their center. Similar to the Dutch part of this study, the U.S. surgeons selected treatment strategies based first on DUS and second on the CTA and scored each for quality and confidence. After a DUS-based treatment was selected, the U.S. reviewers were asked if and why they considered additional imaging to be required. For collection and management of the U.S. data, we utilized the study data REDCap electronic data capture tool hosted at Partners Healthcare and the Brigham and Women's Hospital (Appendix I, available online). 1 Imaging protocols. A vascular ultrasonography technician with >20 years of experience performed DUS exams using a Siemens Acuson S2000 ultrasonography machine. With an insonation angle of <608, a 3.5-MHz curved array, and a 7.5-MHz linear transducer were used for aortoiliac segments and femoral, popliteal, and crural segments respectively. Ankle-brachial indexes were computer-calculated using the ankle artery with the greatest maximal systolic acceleration (maximal slope of the Doppler curve in the early systolic phase). 21 The peak systolic velocity (PSV) was determined in 14 adjacent locations, of which 7 were in the aorto-iliac segments and another 7 in the femoropopliteal segments and PSV ratios were calculated if the PSV was >2.0 m/s. The Dutch vascular diagnostic laboratory uses the following criteria for PSV ratios: PSV ratio of >2.4 indicates a stenosis of $50% and a PSV ratio of >5.4 indicates a stenosis of $75%. DUS findings are documented in a written report and drawn onto a map of the arteries of the lower extremities (Fig) . CTA of the lower limbs was performed using a Toshiba Aquilion-64 or Aquilion-one. A scan is acquired from the celiac trunk to the tibia platform (1 mm), followed by 0.5-mm coupes extending from the femoral condyles to the feet. The first part of scanning was operated at 120 kV and dosis modulation and the second part at 100 kV at fixed m A (100 m A). Scans were acquired with a helical pitch of 5.3 in the 64-slice mode (64 3 0.5 mm). The start of the scan was determined by bolus-triggering measured in the abdominal aorta. Contrast administration involved intravenous injection of 120 mL of contrast medium (I 370 ) at 4 mL/s. Statistical analysis. Agreement between DUSand CTA-based treatment plans and interobserver agreement for treatment planning on DUS or CTA were calculated using kappa (k) statistics with 95% CIs. Agreement was calculated based on the actual treatment plans (eg, bypass graft procedure or endarterectomy). For interpretation of k-values, the following categories for agreement were used: Less than chance (k < 0), slight (k = 0.01-0.20), fair (k = 0.21-0.40), moderate (k = 0.41-0.60), substantial (k = 0.61-0.80), and almost perfect agreement (k = 0.81-0.99). 22 Scores for quality and confidence on DUS and CTA were assessed per reviewer (signed rank test), between reviewers (Friedman analysis of variance by ranks), and overall (mixed (random and fixed effects) methods linear models to account for clustering per patient). In addition, DUS quality and confidence scores and clinical factors of cases for which the DUS-based treatment plan was impacted by the addition of CTA were investigated separately using mixed linear models. Data management and analyses were performed using SAS 9.3 (SAS Institute Inc, Cary, NC).
RESULTS
Cohort. Of the 12 patients included in this study, 9 (75%) were claudicants, and 3 (25%) were critical limb ischemia patients with rest pain and no tissue loss. Mean age was 61 years (range, 42-73) and 10 (83%) were men. The most common comorbidities were coronary artery disease (33%), diabetes (25%), and hypertension (25%). Most patients were known to have PAD (8 patients; 67%), and all of those had received previous exercise therapy (25%), endovascular revascularization (33%), or open operative revascularization (17%).
Impact of added CTA on the treatment strategy. Our 3 reviewers formulated treatment strategies for our cohort of 12 patients, which resulted in 36 treatment strategies (3 3 12) that consisted of a DUS-based treatment plan and a plan based on the added CTA. In 27 strategies (75%), CTA plans were consistent with the DUS-based treatment plans. In 6 strategies (17%), CTA changed the DUS-based strategies. More specifically, 5 treatment plans (14%) for conservative management were turned into interventions, and 1 endovascular revascularization (3%) was turned into an open surgical approach owing to the addition of CTA (Table I ). The added CTA never impacted or changed the approach when open operative treatment had been selected based on DUS, which was the case in 14 treatment strategies (39%). Another strategies 3 (8%) were not changed but merely supplemented owing to added CTA as follows: A PTA treatment plan was supplemented with an open surgical bypass and endarterectomy, a plan for endarterectomy was supplemented with a stent procedure, and a treatment plan for bypass and stenting was supplemented with endarterectomy. Overall, the 9 treatment strategies (25%) that were impacted by the addition of CTA, either changed or supplemented, were distributed over 6 individual patients (patients 1, 3, and 10 for 2 reviewers; and 9, 11, and 12 for 1 reviewer). Analysis of patient and clinical factors that might predict impact for CTA showed no association.
Agreement between treatment plans. Agreement between plans that reviewers based on DUS with plans based on CTA resulted in a mean kappa value of 0.68, which corresponds to substantial agreement (k reviewer(r) 1 Table II) . Agreement between reviewers was less and showed similar mean kappa values for treatment planning based on DUS (mean k, 0.24) and based on CTA (mean k, 0.23).
Quality and confidence. CTA received greater mean scores for quality (4.4 vs 3.3; P < .0001) and confidence for treatment planning (4.4 vs 3.3; P < .0001) than DUS (Table III) . Whereas all mean quality scores were greater for CTA than for DUS, this difference was only significant for reviewer 2 (U.S.), who scored CTA highly. Therapeutic confidence scores of U.S. reviewers were significantly greater on CTA than on DUS. For the Dutch group of clinicians, the difference in confidence scores for the 2 modalities was not significant (CTA 4.6 vs DUS 4.0; P = .2500). Among reviewers, scoring behavior was significantly different for all quality and confidence scores with the exception of DUS quality, which received low scores in a more similar fashion. The mean therapeutic confidence score of the reviewers based on DUS showed an average increase of 30% with the addition of CTA (3.3 to 4.4; P < .0001).
Lesser scores for quality and confidence corresponded to the impact of CTA, because cases for which CTA affected the DUS-based treatment strategy had lesser mean scores than cases for which the strategy was not affected by added CTA (quality, 2.5 vs 3.5; confidence, 2.6 vs 3.5). These affected cases were associated with lesser quality of DUS (P < .0001) and lesser confidence of DUS (P = .028) while accounting for different reviewers. Furthermore, all reviewers scored DUS quality and confidence of these cases with 1 point less than their own average for these DUS scores.
Additional imaging requests. The 2 U.S. surgeons expressed the need for additional imaging in 10 (83%) and 5 (42%) cases, respectively (63% on average), and they indicated that the subsequently added CTA provided them with information they had found lacking on DUS in nearly all cases (70% and 100%, respectively). Of the 15 cases in which a reviewer had requested additional imaging, only 4 were impacted subsequently by the added CTA. More specifically, of the 10 (reviewer 1) and 5 (reviewer 2) requests for additional imaging, the subsequently added CTA impacted the treatment approach for 1 (10%) and 3 (60%) of these cases. The reasons for additional imaging requests ranged from a general lack of confidence in the DUS examination for a certain area to the need for more specifics to better assess the possibility of endovascular therapy (Appendix II, available online). Together, the 2 U.S. reviewers requested additional imaging in 15 cases, of which 7 rationales could be categorized as ''inaccurate information or visualization on DUS,'' another 7 as ''the need for more specifics or detail to allow for treatment planning,'' and one regarded an issue of low confidence only.
DISCUSSION
In this pilot study, treatment planning of clinicians was largely consistent between DUS the addition of a CTA but subject to variability among different reviewers. Although clinicians often felt additional imaging was needed for more specifics and confidence, added CTA did not impact the majority of treatment plans. The level of agreement between DUS-and CTA-based planning has not been investigated before, but our kappa values for substantial agreement are consistent with, 8, 23, 24 or even less than, [25] [26] [27] prior publications on DUSbased treatment planning that used angiography as the reference test. Moreover, the added CTAs in our study did not affect any of the DUS-based plans for open operative treatment, which supports the previously demonstrated utility of DUS in planning for open operative revascularization. 28 Impact of additional CTA. From a clinical point of view, it is important to appreciate the impact of an additional CTA on the ''conservative,'' ''endovascular,'' or ''open surgical'' approach that was selected based on DUS. An endovascular plan was converted into an open surgical approach in only 1 case. Such a conversion is considered less harmful than a shift in the opposite direction, which never occurred in our study, because all DUS-based plans for open operative revascularizations were not affected and merely confirmed by additional CTA.
Clinician confidence. Additional CTA did change the DUS-based plans for a conservative approach into an interventional approach. Remarkably, all but one of those changes had been selected by Dutch reviewers, who showed no difference between confidence on DUS and on CTA, as did the U.S. reviewers; however, we can note that the Dutch clinicians also expressed the need frequently for additional imaging at the Dutch multidisciplinary meeting. Their residents being less experienced have particularly expressed the need for additional imaging to confidently formulate a treatment strategy. This observation could imply that their initial selection of a conservative approach was reflective of a lack of confidence to select a more invasive, interventional approach. Our result of a 30% mean increase in confidence scores owing to added CTA is difficult to interpret, but given the frequent requests for additional imaging, this observation could imply that this increase in confidence is relevant to clinicians. Yet, the correlation between confidence and orders for additional imaging does differ per individual clinician. One of the U.S. reviewers requested additional imaging in many cases, but these requests did not seem to correlate well with the actual impact of the added CTA imaging. The other reviewer predicted an impact of added imaging better, and his expressed need for additional imaging (42%) was in line with estimates of previous studies that assessed the need for additional imaging after DUS. 10, 17 Limitations. The small sample size and the use of a single vascular technician limit markedly the generalizability of our results to other centers. We also recognize that, particularly for the U.S. reviewers, artificial circumstances of the study design can be a limitation compared with real-world practice, because collecting one's own medical history and physical examination data would affect greatly confidence in imaging. In an effort to best inform the U.S. reviewers in this study, we provided them with written documentation of all clinical information of cases as presented at the Dutch meeting. Based on prior publications, our findings might even underestimate the potential of DUS for treatment planning, and the value of additional imaging might even be of less than found in this study. 3, 12, [25] [26] [27] The variability in treatment planning and scoring behavior of reviewers is an important limitation of this study. This variability might partially be the result of our multinational study design and the fact that one reviewer's decisions were based on consensus, whereas others decided individually. We realized that the U.S. reviewers had a lesser comfort level with DUS at baseline compared with the Dutch surgeons, for whom DUS is more common practice for these patients. Yet, we deliberately chose to include both the Dutch and U.S. reviewers, because this enabled us to assess DUS-and CTA-based planning in settings with different utilization rates of these imaging types. Uncertainty and unfamiliarity among these reviewers might have contributed to a greater variability for treatment planning; however, interobserver agreement was not greater between surgeons of the same nationality, because agreement on treatment planning was not necessarily greater between the U.S. reviewers. Furthermore, we chose to compare the individually composed treatment plans of the U.S. surgeons with the Dutch consensus-based plans, because we wanted to assess treatment planning as close to the real clinical practice settings as possible. In the United States, surgeons formulate treatment plans for their patients more autonomously, whereas in the Dutch institution, treatment plans seem to be the result of group evaluation based on consensus of colleagues. In fact, the Dutch patients had received the final treatment plan formulated at the Dutch meeting, which is the CTA-based plan of the Dutch surgeons in our study. A potential for bias may have occurred in the study design that presented clinicians with DUS first and then added CTA. In this manner, greater confidence on CTA could also be the result of more imaging, and the DUSbased treatment planning might be affected by the knowledge that additional CTA will follow anyway. Although it is true that more imaging will probably create more confidence, the question of this study was not so much how clinicians score confidence on CTA, but rather (1) whether clinicians would have enough information and confidence on DUS alone to allow for treatment planning; and (2) what the impact of additional imaging would be. If clinician confidence on DUS is too low, additional imaging will be required, regardless of the associated costs, time, and invasiveness. Although our DUS technician was very experienced, both U.S. and Dutch clinicians often expressed the need for additional imaging, which implies that the DUS examinations often did not meet the expectations of clinicians and the requirements of clinical decision making. As in many other publications in this field, we highlight the need for internal validation of technicians, clinicians, and a close relationship between these 2 before adopting a workup with DUS only, because the utility of DUS is known to be dependent on the skills of technicians and confidence and trust of clinicians. 3 Future directions and recommendations. While recognizing variability between centers and clinicians, this study identified the obstacle of clinician confidence as a factor that could hamper greater use of DUS in the appropriate clinical settings. We suggest that sites that are looking to use DUS more often before PAD interventions might want to start with a workup that includes both DUS and another imaging modality such as CTA to improve familiarity and confidence with less invasive imaging. In this manner, they can first match the technical aspects of the DUS results with the confidence of the surgeons on the user end to finally be able to have a work up with DUS alone as the initial tool for decision making. 13 Greater adoption of DUS can be beneficial to both patient safety and health care costs because this inexpensive modality limits patient exposure to intravenous contrast agents and radiation, and saves the expense of care for contrast-associated complications. At the same time, it is important to realize that additional factors will influence institutional utilization of imaging modalities, such as financial incentives, which may be different for vascular surgeons practicing in different systems of health care and compensation. 16 We suggest that for the U.S. surgeons practicing in a fee-for-service environment, financial factors may have greater influence than for the salaried Dutch surgeons.
We believe this work illustrates that, although clinicians might be able to plan PAD treatment based on DUS alone, clinician confidence is an important impediment to relying on DUS alone in the decision-making process. Greater use of DUS as an initial decision-making tool may help to decrease the number of redundant imaging studies that are associated with additional costs, time, and invasiveness. The variability found in treatment planning, clinician confidence, and requests for additional imaging demonstrate the complexity of the clinical decision-making process with PAD. Although studies on the decision making process of clinicians are cumbersome, larger studies are required to better understand the clinician's motivation to order additional imaging and to explore the potential for DUS to serve as a primary decision tool.
